| UK-1 and structural analogs are potent inhibitors of hepatitis C virus replication DN Ward, DC Talley, M Tavag, S Menji, P Schaughency, A Baier, ... Bioorganic & medicinal chemistry letters 24 (2), 609-612, 2014 | 21 | 2014 |
| Chlorcyclizine inhibits viral fusion of hepatitis C virus entry by directly targeting HCV envelope glycoprotein 1 Z Hu, A Rolt, X Hu, CD Ma, DJ Le, SB Park, M Houghton, N Southall, ... Cell chemical biology 27 (7), 780-792. e5, 2020 | 20 | 2020 |
| Chemoprotective antimalarials identified through quantitative high-throughput screening of Plasmodium blood and liver stage parasites D Dorjsuren, RT Eastman, KJ Wicht, D Jansen, DC Talley, BA Sigmon, ... Scientific reports 11 (1), 2121, 2021 | 17 | 2021 |
| Identification and profiling of a novel diazaspiro [3.4] octane chemical series active against multiple stages of the human malaria parasite plasmodium falciparum and … C Le Manach, J Dam, JG Woodland, G Kaur, LP Khonde, C Brunschwig, ... Journal of medicinal chemistry 64 (4), 2291-2309, 2021 | 16 | 2021 |
| Benzimidazole and benzoxazole zinc chelators as inhibitors of metallo‐β‐lactamase NDM‐1 AC Jackson, TBJ Pinter, DC Talley, A Baker‐Agha, D Patel, PJ Smith, ... ChemMedChem 16 (4), 654-661, 2021 | 15 | 2021 |
| Optimization of high-throughput methyltransferase assays for the discovery of small molecule inhibitors G Dong, A Yasgar, DL Peterson, A Zakharov, D Talley, KCC Cheng, ... ACS combinatorial science 22 (8), 422-432, 2020 | 15 | 2020 |
| Progress towards synthetic chlorins with graded polarity, conjugatable substituents, and wavelength tunability D Ra, KA Gauger, K Muthukumaran, T Balasubramanian, ... Journal of porphyrins and phthalocyanines 19 (04), 547-572, 2015 | 12 | 2015 |
| Hybrid In Silico Approach Reveals Novel Inhibitors of Multiple SARS-CoV-2 Variants S Jain, DC Talley, B Baljinnyam, J Choe, Q Hanson, W Zhu, M Xu, ... ACS Pharmacology & Translational Science 4 (5), 1675-1688, 2021 | 10 | 2021 |
| Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion CD Ma, M Imamura, DC Talley, A Rolt, X Xu, AQ Wang, D Le, T Uchida, ... Nature microbiology 5 (12), 1532-1541, 2020 | 10 | 2020 |
| Real-time cellular thermal shift assay to monitor target engagement TW Sanchez, MH Ronzetti, AE Owens, M Antony, T Voss, E Wallgren, ... ACS Chemical Biology 17 (9), 2471-2482, 2022 | 8 | 2022 |
| Allosteric binders of ACE2 are promising anti-SARS-CoV-2 agents JE Hochuli, S Jain, C Melo-Filho, ZL Sessions, T Bobrowski, J Choe, ... ACS Pharmacology & Translational Science 5 (7), 468-478, 2022 | 7 | 2022 |
| A small-molecule inhibitor and degrader of the RNF5 ubiquitin ligase J Ruan, D Liang, W Yan, Y Zhong, DC Talley, G Rai, D Tao, CA LeClair, ... Molecular Biology of the Cell 33 (13), ar120, 2022 | 6 | 2022 |
| Exploring the importance of zinc binding and steric/hydrophobic factors in novel HCV replication inhibitors DC Talley, L Delang, J Neyts, P Leyssen, PJ Smith Bioorganic & Medicinal Chemistry Letters 26 (4), 1196-1199, 2016 | 5 | 2016 |
| Venglustat inhibits protein N-terminal methyltransferase 1 in a substrate-competitive manner G Dong, Y Deng, A Yasgar, R Yadav, D Talley, AV Zakharov, S Jain, ... Journal of medicinal chemistry 65 (18), 12334-12345, 2022 | 3 | 2022 |
| Auranofin targets UBA1 and enhances UBA1 activity by facilitating ubiquitin trans-thioesterification to E2 ubiquitin-conjugating enzymes W Yan, Y Zhong, X Hu, T Xu, Y Zhang, S Kales, Y Qu, DC Talley, ... Nature Communications 14 (1), 4798, 2023 | 2 | 2023 |
| Discovery and optimization of a 4-aminopiperidine scaffold for inhibition of hepatitis C virus assembly A Rolt, DC Talley, SB Park, Z Hu, A Dulcey, C Ma, P Irvin, M Leek, ... Journal of medicinal chemistry 64 (13), 9431-9443, 2021 | 2 | 2021 |
| C-abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same JJ Marugan, M Ferrer, NT Southall, AE Dulcey, X Hu, CR Dextras, ... US Patent App. 18/128,603, 2023 | | 2023 |
| C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same JJ Marugan, M Ferrer, NT Southall, AE Dulcey, X Hu, CR Dextras, ... US Patent 11,649,218, 2023 | | 2023 |
| C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same. RE Von Bernhardi Montgomery, A Dulcey, X Hu, C Dextras, D Talley, ... | | 2023 |
| A real-time cellular thermal shift assay (RT-CETSA) to monitor target engagement TW Sanchez, MH Ronzetti, AE Owens, M Antony, T Voss, E Wallgren, ... bioRxiv, 2022.01. 24.477382, 2022 | | 2022 |
